Bupropion Can Be Prescribed to Elderly Patients with Depression
Yes, bupropion is appropriate for elderly patients with depression and is supported by both FDA labeling and clinical evidence, though it requires dose adjustments and careful monitoring for renal function. For anxiety specifically, the evidence is more nuanced—bupropion can improve comorbid anxiety symptoms in depression but may not be the first choice for severe anxiety disorders.
Evidence from FDA Labeling and Guidelines
The FDA label explicitly addresses geriatric use: No overall differences in safety or effectiveness were observed between elderly subjects (≥65 years) and younger patients in clinical trials 1. However, critical considerations exist:
- Elderly patients are more likely to have decreased renal function, and since bupropion and its metabolites are cleared renally, accumulation can occur
- Dose adjustment is necessary: Consider reduced dose and/or frequency in patients with renal impairment (GFR <90 mL/min) 1
- Monitor closely for adverse reactions indicating high drug or metabolite exposures
The American College of Physicians guidelines 2 recommend selecting second-generation antidepressants based on adverse effect profiles, cost, and patient preferences, as no second-generation antidepressant demonstrates superior efficacy over others for depression. Notably, bupropion is associated with lower rates of sexual adverse events compared to SSRIs 2—a significant advantage in elderly patients where polypharmacy and quality of life are paramount concerns.
Clinical Evidence in Elderly Depression
The strongest recent evidence comes from a 2010 placebo-controlled trial 3 demonstrating that extended-release bupropion (150-300 mg once daily) is effective and well-tolerated in patients ≥65 years, with statistically significant improvements in depression scores and health outcomes including motivation, energy, and life satisfaction. Adverse events were mild to moderate and similar to placebo.
Additional supporting evidence:
- A 2000 head-to-head trial 4 showed bupropion SR was equally effective as paroxetine in elderly patients (ages 60-88), with comparable efficacy on all depression rating scales
- A 2001 naturalistic study 5 found 74% response rates and 53% remission rates in elderly patients with major depression, including those with high medical comorbidity
- A 2011 case series 6 demonstrated effectiveness even in treatment-resistant elderly patients, with significant improvements in depression scores
The Anxiety Question: A Critical Distinction
For depression with comorbid anxiety symptoms, bupropion appears effective and does not worsen anxiety in most patients 7, 8, 9. The most recent 2025 systematic review 8 found that bupropion provides clinically relevant improvement in anxiety symptoms in adults with major depressive disorder, with generally comparable efficacy to SSRIs in most presentations.
However, important caveats:
- SSRIs showed a modest advantage in patients with HIGH baseline anxiety 8
- Bupropion's stimulating properties can provoke anxiety, particularly at higher doses 7
- A 2023 naturalistic study 9 using propensity matching found no difference in anxiety outcomes between bupropion and SSRIs over 12 weeks—anxiety improved comparably in both groups
For primary anxiety disorders without depression, bupropion is not FDA-approved and SSRIs remain preferred 7.
Practical Prescribing Algorithm for Elderly Patients
Step 1: Assess Renal Function
- Check GFR before initiating
- If GFR <90 mL/min: reduce dose and/or frequency 1
- If moderate-severe hepatic impairment: maximum 150 mg every other day 1
Step 2: Determine Anxiety Severity
- Mild-moderate comorbid anxiety with depression: Bupropion is appropriate
- Severe anxiety or primary anxiety disorder: Consider SSRI as first-line
- Sexual dysfunction concerns or prior SSRI intolerance: Bupropion offers clear advantage 2
Step 3: Dosing Strategy
- Start low: Begin with 150 mg once daily (extended-release formulation)
- Titrate cautiously: Can increase to 300 mg daily based on response and tolerability 3, 4
- Monitor within 1-2 weeks of initiation for suicidality, agitation, or unusual behavioral changes 2
Step 4: Assess Response
- Evaluate at 6-8 weeks; modify treatment if inadequate response 2
- Elderly patients may require longer treatment periods (up to 12 weeks) for full response 5
Key Pitfalls to Avoid
- Ignoring renal function: Elderly patients commonly have reduced GFR even with normal creatinine; calculate GFR and adjust accordingly
- Starting at standard adult doses: The elderly are at risk for accumulation of bupropion and metabolites 10
- Dismissing bupropion for any anxiety: Comorbid anxiety in depression is different from primary anxiety disorders—bupropion can improve the former 8, 9
- Overlooking medication advantages: In elderly patients with sexual dysfunction from SSRIs or those needing smoking cessation, bupropion offers dual benefits 2, 11